cjc 1295 vs ipamorelin CJC-1295 vs. Ipamorelin + CJC-1295: Peptide Combo

Growth hormone promotes lipolysis (fat breakdown) and shifts metabolism toward preferential use of fat for energy

Side Effects & Safety Typical first-cycle side effects: Weeks 1-2: mild water retention, vivid dreams, light head/warmth after injection Weeks 3-4: occasional joint stiffness, improved sleep quality, slight appetite increase overnight Weeks 5-8: adaptation phase most side effects fade, body composition changes visible Clinical discontinuation signals (trial-reported): Clinical participants in tesamorelin studies were discontinued upon experiencing: Persistent headaches with visual changes (intracranial pressure marker in trial monitoring protocols) Sustained fasting glucose elevation of ~15 mg/dL above baseline Unusual peripheral swelling persisting beyond weeks 1-2 Carpal tunnel symptoms unresponsive to dose titration in community-reported protocols Tesamorelin has been studied at 2mg/day for 6+ months without notable safety signals at therapeutic doses

Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy

For athletes, this translates into leaner gains, faster recovery, and better body composition without disrupting the bodys natural endocrine rhythm